These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 30664566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries.
    Dalzell AM, Ba'Ath ME.
    Paediatr Int Child Health; 2019 Feb; 39(1):48-58. PubMed ID: 30900526
    [Abstract] [Full Text] [Related]

  • 3. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
    Bokemeyer B, Dignaß A, Schreiber S.
    Z Gastroenterol; 2017 Apr; 55(4):369-374. PubMed ID: 28056484
    [Abstract] [Full Text] [Related]

  • 4. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M, Duricova D, Bortlik M, Hruba V, Machkova N, Mitrova K, Malickova K, Lukas M, Lukas M.
    Dig Dis; 2017 Apr; 35(1-2):91-100. PubMed ID: 28147356
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, Kaplan GG, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN.
    J Crohns Colitis; 2020 Oct 05; 14(10):1354-1363. PubMed ID: 32648579
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
    Tepeš K, Hanžel J, Štubljar D, Strmšek K, Erjavec L, Supovec E, Jagodic Z, Končan M, Grosek J, Košir JA, Tomažič A, Kogovšek U, Norčič G, Šibli R, Žnidaršič M, Pačnik Vižintin T, Sodin B, Breznik J, Hribar VA, Ocepek A, Pernat Drobež C, Bukovnik N, Zafošnik A, Marušič T, Jurečič Brglez N, Denkovski M, Smrekar N, Novak G, Koželj M, Kurent T, Simonič J, Pintar Š, Štabuc B, Drobne D.
    Eur J Gastroenterol Hepatol; 2024 Jun 01; 36(6):728-734. PubMed ID: 38625825
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A national survey on the patterns of treatment of inflammatory bowel disease in Canada.
    Hilsden RJ, Verhoef MJ, Best A, Pocobelli G.
    BMC Gastroenterol; 2003 Jun 05; 3():10. PubMed ID: 12791168
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents.
    Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC, European Society of Pediatric Gastroenterology, Hepatology, and Nutrition.
    J Pediatr Gastroenterol Nutr; 2014 Jun 05; 58(6):795-806. PubMed ID: 24231644
    [Abstract] [Full Text] [Related]

  • 18. [Application of the Porto criteria for the diagnosis of paediatric inflammatory bowel disease in a paediatric reference centre].
    Martín de Carpi J, Vila V, Varea V.
    An Pediatr (Barc); 2011 Oct 05; 75(4):232-8. PubMed ID: 21549650
    [Abstract] [Full Text] [Related]

  • 19. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
    Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D.
    J Crohns Colitis; 2017 Oct 01; 11(10):1230-1237. PubMed ID: 28605483
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.